PROCEPT BioRobotics Shares Drop 8% After Leerink Downgrade
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 11 2026
0mins
Source: seekingalpha
- Downgrade Impact: PROCEPT BioRobotics shares fell 8% on Thursday after Leerink Partners downgraded the stock from Outperform to Market Perform and lowered its price target from $31 to $29, indicating reduced confidence in the company's near-term growth outlook.
- Rising Competitive Risks: Leerink's analysis highlights increasing adoption of prostate artery embolization (PAE) as a less invasive treatment for benign prostatic hyperplasia, which could negatively impact demand for PROCEPT's Aquablation therapy, intensifying market competition.
- Financial Forecast Adjustments: The firm cut its fiscal 2026 procedure and revenue forecasts for PROCEPT, now slightly below Wall Street consensus and near the low end of management's guidance range, reflecting a more cautious stance on the company's future performance.
- Execution Risk Alerts: Changes in the company's handpiece purchasing strategy may lead to uncertainty around channel inventory dynamics, while potential execution risks tied to the sales force realignment could limit future market potential for the HYDROS system.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PRCT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PRCT
Wall Street analysts forecast PRCT stock price to rise
10 Analyst Rating
8 Buy
2 Hold
0 Sell
Strong Buy
Current: 20.910
Low
38.00
Averages
51.75
High
65.00
Current: 20.910
Low
38.00
Averages
51.75
High
65.00
About PRCT
PROCEPT BioRobotics Corporation is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. The Company develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, which are advanced, image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia (BPH). It designed Aquablation therapy to deliver outcomes for males suffering from lower urinary tract symptoms (LUTS), due to BPH that is independent of prostate size and shape and delivers resection independent of surgeon experience. It manufactures the robotic systems, the single-use disposable handpiece, integrated scope and other accessories at its facility in San Jose, California. Each robotic system is shipped to its customers with a third-party manufactured ultrasound system and probe.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
PROCEPT BioRobotics Shares Drop 8% After Leerink Downgrade
- Downgrade Impact: PROCEPT BioRobotics shares fell 8% on Thursday after Leerink Partners downgraded the stock from Outperform to Market Perform and lowered its price target from $31 to $29, indicating reduced confidence in the company's near-term growth outlook.
- Rising Competitive Risks: Leerink's analysis highlights increasing adoption of prostate artery embolization (PAE) as a less invasive treatment for benign prostatic hyperplasia, which could negatively impact demand for PROCEPT's Aquablation therapy, intensifying market competition.
- Financial Forecast Adjustments: The firm cut its fiscal 2026 procedure and revenue forecasts for PROCEPT, now slightly below Wall Street consensus and near the low end of management's guidance range, reflecting a more cautious stance on the company's future performance.
- Execution Risk Alerts: Changes in the company's handpiece purchasing strategy may lead to uncertainty around channel inventory dynamics, while potential execution risks tied to the sales force realignment could limit future market potential for the HYDROS system.
See More
PROCEPT BioRobotics Reports Strong Q1 2026 Revenue Growth
- Significant Revenue Growth: PROCEPT BioRobotics reported Q1 2026 revenue of $83.1 million, a 20% increase from $69.2 million year-over-year, with U.S. revenue at $72.0 million, reflecting strong demand and improved sales execution for its Aquablation platform.
- Increased Procedure Volume: Approximately 12,200 Aquablation procedures were performed in the U.S. during Q1, marking a 30% increase from the prior year, indicating substantial progress in market penetration and customer acceptance of the technology.
- Technology Innovation Approved: The company received FDA clearance for its second-generation First Assist AI software, enhancing personalized, image-guided planning for Aquablation therapy, which strengthens the consistency and effectiveness of its next-generation HYDROS robotic system.
- Optimistic 2026 Outlook: PROCEPT reaffirmed its 2026 revenue guidance of $390 million to $410 million, representing a 27% to 33% growth, with U.S. procedure growth expected between 39% and 48%, demonstrating confidence in future market opportunities.
See More
PROCEPT BioRobotics Q1 2026 Earnings Call Insights
- Revenue Performance: In Q1 2026, PROCEPT BioRobotics achieved total revenue of $83.1 million, showing significant growth compared to the previous quarter, indicating the company's resilience and growth potential, with full-year revenue expected to range between $390 million and $410 million.
- Margin Improvement: The company reported a gross margin of 65% for Q1, up from 61% in Q4 2025, reflecting successful pricing discipline and cost structure optimization, which is expected to lay the groundwork for future profitability.
- System Sales Dynamics: PROCEPT sold 49 Hydros systems in the first quarter, with an average selling price of approximately $485,000, demonstrating the company's competitiveness in the high-end medical device market and providing a solid foundation for future sales growth.
- Market Expansion Plans: The company launched the Hydros system in the U.K. for the first time and received a strong recommendation from updated EAU clinical guidelines, which is expected to further drive market acceptance and sales growth for Aquablation therapy, enhancing the company's influence in international markets.
See More
Procept Releases Financial Guidance for FY 2026
- Earnings Beat: Procept's Q1 GAAP EPS of $0.56 exceeds expectations by $1.12, indicating strong performance and improved profitability in the surgical robotics market.
- Significant Revenue Growth: The company reported Q1 revenue of $83.13 million, a 20.1% year-over-year increase, surpassing expectations by $2.59 million, reflecting sustained demand in the surgical robotics sector.
- 2026 Financial Guidance: Procept anticipates full-year 2026 revenue between $390 million and $410 million, representing a growth of 27% to 33% compared to the previous year, showcasing a positive outlook for future market conditions.
- Procedure Growth Expectations: The company expects U.S. procedure growth for 2026 to range from 39% to 48%, highlighting strong growth potential in the surgical robotics market and reinforcing its competitive position.
See More
Procept Scheduled to Announce Q1 Earnings with Mixed Estimates
- Earnings Announcement Date: Procept (PRCT) is set to release its Q1 2023 earnings on April 29th after market close, with consensus EPS estimate at -$0.56 and revenue estimate at $80.54 million, reflecting a 16.4% year-over-year growth.
- Performance Expectations: Over the past year, Procept has only beaten EPS estimates 25% of the time, while achieving a 100% success rate in beating revenue estimates, indicating stability in revenue but a need for improvement in profitability.
- Estimate Revision Trends: In the last three months, there have been no upward revisions to EPS estimates, with 6 downward adjustments, and similarly, revenue estimates saw no upward revisions but 7 downward adjustments, suggesting market caution regarding the company's future performance.
- Long-term Revenue Goals: Procept has set a revenue target of $390 million to $410 million for 2026, and despite current performance missing expectations, the company aims to enhance its outlook through pricing discipline and commercial realignment, demonstrating confidence in future growth prospects.
See More
Chicago Capital Increases Stake in PROCEPT BioRobotics
- Increased Holdings: Chicago Capital increased its stake in PROCEPT BioRobotics by 969,592 shares in Q1 2026, valued at approximately $27.32 million, bringing its ownership to 1.46%, indicating confidence in the company's growth potential.
- Stock Volatility: As of April 23, 2026, PROCEPT shares were priced at $24.24, down 56.5% year-over-year, reflecting significant volatility typical in the medical device sector, raising concerns about its profitability.
- Sales Growth: Since 2022, the number of procedures performed using PROCEPT's AquaBeam system surged from 7,400 to 43,000, while the installed base increased from 167 to 718, demonstrating strong market acceptance of its minimally invasive solutions.
- Improved Profitability: Although still unprofitable, PROCEPT's EBITDA margins improved from -91% to -16%, and gross margins rose from 49% to 64%, indicating the potential for future profitability and competitive strength in the market.
See More
PROCEPT BioRobotics Shares Drop 8% After Leerink Downgrade
- Downgrade Impact: PROCEPT BioRobotics shares fell 8% on Thursday after Leerink Partners downgraded the stock from Outperform to Market Perform and lowered its price target from $31 to $29, indicating reduced confidence in the company's near-term growth outlook.
- Rising Competitive Risks: Leerink's analysis highlights increasing adoption of prostate artery embolization (PAE) as a less invasive treatment for benign prostatic hyperplasia, which could negatively impact demand for PROCEPT's Aquablation therapy, intensifying market competition.
- Financial Forecast Adjustments: The firm cut its fiscal 2026 procedure and revenue forecasts for PROCEPT, now slightly below Wall Street consensus and near the low end of management's guidance range, reflecting a more cautious stance on the company's future performance.
- Execution Risk Alerts: Changes in the company's handpiece purchasing strategy may lead to uncertainty around channel inventory dynamics, while potential execution risks tied to the sales force realignment could limit future market potential for the HYDROS system.
See More
PROCEPT BioRobotics Reports Strong Q1 2026 Revenue Growth
- Significant Revenue Growth: PROCEPT BioRobotics reported Q1 2026 revenue of $83.1 million, a 20% increase from $69.2 million year-over-year, with U.S. revenue at $72.0 million, reflecting strong demand and improved sales execution for its Aquablation platform.
- Increased Procedure Volume: Approximately 12,200 Aquablation procedures were performed in the U.S. during Q1, marking a 30% increase from the prior year, indicating substantial progress in market penetration and customer acceptance of the technology.
- Technology Innovation Approved: The company received FDA clearance for its second-generation First Assist AI software, enhancing personalized, image-guided planning for Aquablation therapy, which strengthens the consistency and effectiveness of its next-generation HYDROS robotic system.
- Optimistic 2026 Outlook: PROCEPT reaffirmed its 2026 revenue guidance of $390 million to $410 million, representing a 27% to 33% growth, with U.S. procedure growth expected between 39% and 48%, demonstrating confidence in future market opportunities.
See More
PROCEPT BioRobotics Q1 2026 Earnings Call Insights
- Revenue Performance: In Q1 2026, PROCEPT BioRobotics achieved total revenue of $83.1 million, showing significant growth compared to the previous quarter, indicating the company's resilience and growth potential, with full-year revenue expected to range between $390 million and $410 million.
- Margin Improvement: The company reported a gross margin of 65% for Q1, up from 61% in Q4 2025, reflecting successful pricing discipline and cost structure optimization, which is expected to lay the groundwork for future profitability.
- System Sales Dynamics: PROCEPT sold 49 Hydros systems in the first quarter, with an average selling price of approximately $485,000, demonstrating the company's competitiveness in the high-end medical device market and providing a solid foundation for future sales growth.
- Market Expansion Plans: The company launched the Hydros system in the U.K. for the first time and received a strong recommendation from updated EAU clinical guidelines, which is expected to further drive market acceptance and sales growth for Aquablation therapy, enhancing the company's influence in international markets.
See More
Procept Releases Financial Guidance for FY 2026
- Earnings Beat: Procept's Q1 GAAP EPS of $0.56 exceeds expectations by $1.12, indicating strong performance and improved profitability in the surgical robotics market.
- Significant Revenue Growth: The company reported Q1 revenue of $83.13 million, a 20.1% year-over-year increase, surpassing expectations by $2.59 million, reflecting sustained demand in the surgical robotics sector.
- 2026 Financial Guidance: Procept anticipates full-year 2026 revenue between $390 million and $410 million, representing a growth of 27% to 33% compared to the previous year, showcasing a positive outlook for future market conditions.
- Procedure Growth Expectations: The company expects U.S. procedure growth for 2026 to range from 39% to 48%, highlighting strong growth potential in the surgical robotics market and reinforcing its competitive position.
See More
Procept Scheduled to Announce Q1 Earnings with Mixed Estimates
- Earnings Announcement Date: Procept (PRCT) is set to release its Q1 2023 earnings on April 29th after market close, with consensus EPS estimate at -$0.56 and revenue estimate at $80.54 million, reflecting a 16.4% year-over-year growth.
- Performance Expectations: Over the past year, Procept has only beaten EPS estimates 25% of the time, while achieving a 100% success rate in beating revenue estimates, indicating stability in revenue but a need for improvement in profitability.
- Estimate Revision Trends: In the last three months, there have been no upward revisions to EPS estimates, with 6 downward adjustments, and similarly, revenue estimates saw no upward revisions but 7 downward adjustments, suggesting market caution regarding the company's future performance.
- Long-term Revenue Goals: Procept has set a revenue target of $390 million to $410 million for 2026, and despite current performance missing expectations, the company aims to enhance its outlook through pricing discipline and commercial realignment, demonstrating confidence in future growth prospects.
See More
Chicago Capital Increases Stake in PROCEPT BioRobotics
- Increased Holdings: Chicago Capital increased its stake in PROCEPT BioRobotics by 969,592 shares in Q1 2026, valued at approximately $27.32 million, bringing its ownership to 1.46%, indicating confidence in the company's growth potential.
- Stock Volatility: As of April 23, 2026, PROCEPT shares were priced at $24.24, down 56.5% year-over-year, reflecting significant volatility typical in the medical device sector, raising concerns about its profitability.
- Sales Growth: Since 2022, the number of procedures performed using PROCEPT's AquaBeam system surged from 7,400 to 43,000, while the installed base increased from 167 to 718, demonstrating strong market acceptance of its minimally invasive solutions.
- Improved Profitability: Although still unprofitable, PROCEPT's EBITDA margins improved from -91% to -16%, and gross margins rose from 49% to 64%, indicating the potential for future profitability and competitive strength in the market.
See More
